Joins UK consortium to help efficiently manufacture oral solid dosage medication
After the addition of PwC to the mix a couple weeks ago, CPI announced an agreement today with Pfizer, making it the newest partner of the Medicines Manufacturing Innovation Centre collaboration. The partnership will allow the Centre to draw upon Pfizer's pharma knowledge to help address key challenges and maximize efficiency within the medicines supply chain.
Pfizer will work alongside CPI, the University of Strathclyde, PwC and founding industry partners GSK and AstraZeneca. The Centre’s goal is to advance emergent and disruptive technologies through various flagship “Grand Challenge” projects to increase productivity and patient outcomes in the pharma industry.
The new partnership with Pfizer will prioritize Grand Challenge 1, which looks to create an innovative continuous direct compression (CDC) platform that enables oral solid dosage medicines to be formulated more efficiently. The CDC platform will include a digital twin and data predictor model to allow for the modeling of processes in a digital space. This capability is expected to improve efficacy and decrease the quantity of starting materials needed to enhance formulations, with the objective of encouraging companies to develop formulations quicker and at a reduced cost.
Pfizer will be providing data, expert skill and knowledge of continuous mixing technology.